8-K
filed November 15, 2023, 6:59 PM ET
ticker FEMY
CIK 0001339005
debt
confidence high
sentiment neutral
materiality 0.65
Femasys enters $6.85M convertible note financing with warrants; three directors resign
FEMASYS INC
- Issued $6.85M principal of 6% senior unsecured convertible notes maturing Nov 2025; conversion price $1.18.
- Investors received Series A warrants (5.8M shares at $1.18, 1-year) and Series B warrants (5.8M shares at $1.475, 5-year).
- Keith Kendall, Anne Morrissey and Wendy Perrow resigned as directors effective Nov 8, 2023; Morrissey disagreed with no-dispute statement.
- PharmaCyte's interim CEO Joshua Silverman to join board; PharmaCyte gets nomination right until <5% ownership or note repaid.
- Nasdaq audit committee compliance temporarily lost after Kendall's resignation, restored by appointing Edward Uzialko.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anne Morrissey resigned as director at FEMASYS INC.
- Action
- resigned
- Role
- director
Exact text from the filing
On November 8, 2023, Keith Kendall, Anne Morrissey and Wendy Perrow informed the Board of their respective resignations as a director of the Company, effective as of that date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Keith Kendall resigned as director at FEMASYS INC.
- Action
- resigned
- Role
- director
Exact text from the filing
On November 8, 2023, Keith Kendall, Anne Morrissey and Wendy Perrow informed the Board of their respective resignations as a director of the Company, effective as of that date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Wendy Perrow resigned as director at FEMASYS INC.
- Action
- resigned
- Role
- director
Exact text from the filing
On November 8, 2023, Keith Kendall, Anne Morrissey and Wendy Perrow informed the Board of their respective resignations as a director of the Company, effective as of that date.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
FEMASYS INC entered into Securities Purchase Agreement with certain accredited investors valued at aggregate principal amount of $6,850,000 (effective 2023-11-14).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- aggregate principal amount of $6,850,000
- Effective
- 2023-11-14
Exact text from the filing
On November 14, 2023, Femasys Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $6,850,000
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
FEMASYS INC entered into Registration Rights Agreement with certain accredited investors (effective 2023-11-14).
- Action
- entry
- Counterparty
- certain accredited investors
- Effective
- 2023-11-14
Exact text from the filing
The Company and the Investors entered into a Registration Rights Agreement (the “Registration Rights Agreement”), pursuant to which the Company will be required to file a resale registration statement (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) to register for resale 100% of the Conversion Shares and the Warrant Shares promptly following Closing
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.